Day: October 18, 2025

CHENNAI, India, Oct. 18, 2025 (GLOBE NEWSWIRE) — Sify Technologies Limited (NASDAQ: SIFY), India’s leading Digital ICT solutions provider with global service capabilities spanning Data Center, Cloud, Networks, Security and Digital services, today announced that it will report its unaudited IFRS financial results for the second quarter ended September 30, 2025 on Saturday, October 25, 2025 before the market opens.  The following Monday, October 27, 2025, Sify will host a conference call at 8:30 AM ET with Mr. Raju Vegesna, Chairman of the Board and Mr. M P Vijay Kumar, Executive Director & Group CFO. Interested parties may participate by dialling +1-888-506-0062 (Toll Free in the U.S. or Canada) or +1-973-528-0011 (International), which will also be simultaneously broadcast live over the Internet at www.sifytechnologies.com/investors...

NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) — The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading is halted in Platinum Analytics Cayman Limited (Nasdaq: PLTS) for additional information requested from the company. Previously, the Securities and Exchange Commission effected a trading suspension in PLTS from 04:00:00 on October 6, 2025 to 23:59:00 on October 17, 2025. The last sale price of the company’s ordinary shares was $17.50.  More information about the SEC’s order can be found at https://www.sec.gov/files/litigation/suspensions/2025/34-104164.pdf. Trading will remain halted until Platinum Analytics Cayman Limited has fully satisfied Nasdaq’s request for additional information. For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM...

NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) — The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading is halted in Etoiles Capital Group Co., Ltd. (Nasdaq: EFTY) for additional information requested from the company. Previously, the Securities and Exchange Commission effected a trading suspension in EFTY from 04:00:00 on October 6, 2025 to 23:59:00 on October 17, 2025. The last sale price of the company’s ordinary shares was $15.02.  More information about the SEC’s order can be found at https://www.sec.gov/files/litigation/suspensions/2025/34-104163.pdf. Trading will remain halted until Etoiles Capital Group Co., Ltd. has fully satisfied Nasdaq’s request for additional information. For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM...

NEW YORK, Oct. 18, 2025 (GLOBE NEWSWIRE) — The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading is halted in Pitanium Limited (Nasdaq: PTNM) for additional information requested from the company. Previously, the Securities and Exchange Commission effected a trading suspension in PTNM from 04:00:00 on October 6, 2025 to 23:59:00 on October 17, 2025. The last sale price of the company’s ordinary shares was $10.39.  More information about the SEC’s order can be found at https://www.sec.gov/files/litigation/suspensions/2025/34-104165.pdf. Trading will remain halted until Pitanium Limited has fully satisfied Nasdaq’s request for additional information. For news and additional information about the company, please contact the company directly or check under the company’s symbol using InfoQuotesSM on the Nasdaq® Web site. For...

NUC-7738 Synergizes with PD-1 Inhibitors to Promote Cancer Cell Death Data Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738 BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA) (“NuCana” or the “Company”) presented data at the European Society for Medical Oncology Congress 2025 (“ESMO”) on a new model system investigating the synergistic effects of NUC-7738 and PD-1 inhibition in primary organoids derived from patients with renal cell carcinoma (“RCC”). Using patient-derived organoids (“PDOs”) from ten patients with RCC and autologous tumor-infiltrating lymphocytes (“TILs”), co-culture experiments reveal that NUC-7738 enhances the effectiveness of PD-1 inhibitors, resulting in increased tumor cell killing. This combinatorial approach may offer a new option for cancers that no longer...

Media Release COPENHAGEN, Denmark; October 18, 2025Updated data from the Phase 1/2 RAINFOL™-01 trial showed rinatabart sesutecan (Rina-S®) 100 mg/m2 demonstrated 50% confirmed objective response rate (ORR), including two complete responses (CR), regardless of FRα expression A Phase 3 trial in endometrial cancer is underway U.S. FDA recently granted Breakthrough Therapy Designation to Rina-S for advanced endometrial cancerGenmab A/S (Nasdaq: GMAB) announced today updated data from cohort B2 of the Phase 1/2 RAINFOL™-01 trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha (FRα)-targeted, TOPO1-inhibitor antibody-drug conjugate (ADC). The study showed that at a median study follow-up of one year, treatment with Rina-S 100 mg/m² every 3 weeks (Q3W) resulted in a 50.0% confirmed objective...

Clinical benefit of the gedatolisib regimens was consistent across patient subgroups  Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant (“gedatolisib triplet”) and in 11.5% of patients treated with gedatolisib + fulvestrant (“gedatolisib doublet”) Study treatment discontinuation due to treatment related adverse events was reported in 2.3% of patients treated with the gedatolisib triplet and 3.1% of patients with the gedatolisib doublet Management to host webcast and conference call October 20, 2025, at 8:00 a.m. ETMINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced detailed efficacy and safety results from the PIK3CA wild-type (“WT”) cohort...

Median radiographic progression free survival (“rPFS”) was 9.1 months and the six-month rPFS rate was 67%No patients discontinued study treatment due to a treatment-related adverse event (“TRAE”)MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updated clinical results from the Phase 1 portion of a clinical trial evaluating gedatolisib in combination with Nubeqa® (darolutamide), an androgen receptor inhibitor, in men with mCRPC whose disease had progressed on prior treatment with a next generation androgen receptor inhibitor. These data were presented at a poster presentation at the European Society of Medical Oncology (ESMO) today, Saturday, at 6:00 a.m. ET/12:00 p.m. CEST. In this Phase...

PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial is fully enrolled Additional analysis of data from a Phase 1b clinical trial that included all patients treated with gedatolisib combined with fulvestrant and palbociclib showed median progression-free survival (“PFS”) of 14.6 months in patients with HR+/HER2-/PIK3CA-mutated advanced breast cancer (“ABC”)MINNEAPOLIS, Oct. 18, 2025 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced updates on the status of the PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial evaluating gedatolisib plus fulvestrant with and without palbociclib versus alpelisib and fulvestrant in adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2...

FTI mechanism addresses innate and adaptive resistance pathways common to targeted oncology therapies Early clinical and preclinical data support darlifarnib’s potential to enhance clinical benefit of PI3Kα-, KRAS- and tyrosine kinase inhibitors 50% objective response rate and 80% disease control rate in renal cell carcinoma (RCC) cohort of darlifarnib plus cabozantinib in ongoing dose-escalation clinical trial Kura Oncology to host a virtual investor event today, October 18, 2025, at 10:30 a.m. PT / 1:30 p.m. ET / 7:30 p.m. CEST SAN DIEGO, Oct. 18, 2025 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced new preliminary data from its farnesyl transferase inhibitor (FTI) programs –...